ArticleFrontiers in pharmacology2025
Scutellarin attenuated tubule cell apoptosis by modulating HIF-1α for the treatment of DKD: the insight integrating network analysis, machine learning and single-cell transcriptome.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baicalein attenuates extracellular matrix remodeling via FN1 in diabetic kidney disease: a multi-omics, machine-learning and mesangial-cell rescue study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To explore the possible mechanism and target of scutellarin (Scu) on diabetic kidney disease (DKD). Method: The Network analysis was used to explore and enrich the possible pathway. RNA transcriptome were employed to deepen the understanding of candidate targets in key signaling pathways. Core targets were optimized through 8 machine learning algorithms. Single-cell transcriptome were utilized to clarify the expression locations and temporal trajectories of core targets, identifying high-expression cell types. Finally, molecular docking and cell experiments were conducted to validate the regulatory effects of Scutellarin on the molecular targets. Result: The Network analysis showed the roles of hypoxic response and apoptosis pathways. RNA transcriptome and machine learning identified HIF-1α and CASP3 as the hub genes related to DKD outcomes and hypoxic apoptosis. Single-cell transcriptome analysis confirmed the expression patterns and locations of hub genes, identifying the CD-PC cells as the high-expression cell type. Conclusion: Scutellarin attenuated renal collecting duct cell apoptosis by modulating HIF-1α for the treatment of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.